A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Cetuximab (Primary) ; Pazopanib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 09 Jul 2018 Results (N=22) assessing pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma published in the Lancet Oncology.
- 06 Jul 2018 Planned End Date changed from 31 May 2018 to 31 Dec 2018.
- 27 Feb 2018 Planned End Date changed from 31 Dec 2017 to 31 May 2018.